Relay Therapeutics (RLAY) and HLB's unit Elevar Therapeutics said Tuesday that the companies agreed to an up to $500 million exclusive global licensing deal for lirafugratinib.
Under the agreement, Relay Therapeutics will receive up to $75 million in upfront and regulatory milestone payments, $425 million in commercial milestone payments, plus double-digit royalties on global sales.
Additionally, Elevar Therapeutics is responsible for the further development and commercialization of lirafugratinib.
Lirafugratinib is currently under development as a potential treatment for bile duct cancer and other fibroblast growth factor receptor 2-altered solid tumors, according to the statement.
Shares of Relay Therapeutics were down 3.4% in recent trading.
Price: 4.51, Change: -0.16, Percent Change: -3.43
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。